Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study

Annals of the Rheumatic Diseases

Volumn 69, Issue 11, 2010, Pages 1996-2001

  Semb, A G ^a   Kvien, T K ^a   Aastveit, A H ^b   Jungner, I ^c   Pedersen, T R ^d   Walldius, G ^c   Holme, I ^d  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ARTICLE; BRAIN ISCHEMIA; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; AGED; BLOOD; CLINICAL TRIAL; EPIDEMIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROGNOSIS; STROKE; SWEDEN;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CHOLESTEROL; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; STROKE; SWEDEN; TRIGLYCERIDES;

EID: 78149492440     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.126128     Document Type: Article

References (55)

1. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation. Ann Rheum Dis 2009;68:1395-400.
2. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008;58:2612-21.
3. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
4. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
5. Steen KS, Lems WF, Visman IM, et al. High incidence of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68:1509-10.
6. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
7. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.
8. Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008;59:1090-6.
9. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
10. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
11. Dessein PH, Joffe BI, Veller MG, et al. Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005;32:435-42.
12. van der Helm-van Mil AH, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007;56:425-32.
13. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001;40:640-4.
14. Roman MJ, Moeller E, Davis A, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249-56.
15. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259:493-519.
16. Holme I, Aastveit AH, Hammar N, et al. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009;265:275-87.
17. Ebrahim S, Sung J, Song YM, et al. Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study. BMJ 2006;333:22.
18. Tirschwell DL, Smith NL, Heckbert SR, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004;63:1868-75.
19. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026-33.
20. Hammar N, Larsen FF, de Faire U. Are geographical differences and time trends in myocardial infarction incidence in Sweden real? Validity of hospital discharge diagnoses. J Clin Epidemiol 1994;47:685-93.
21. Marcovina SM, Albers JJ, Henderson LO, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 1993;39:773-81.
22. Marcovina SM, Albers JJ, Kennedy H, et al. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 1994;40:586-92.
23. Walldius G, Jungner I, Aastveit AH, et al. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004;42:1355-63.
24. Ulm K. A simple method to calculate the confidence interval of a standardized mortality ratio (SMR). Am J Epidemiol 1990;131:373-5.
25. Holme I, Cater NB, Faergeman O, et al. Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease in End-points through Aggressive Lipid-lowering Trial (IDEAL). Ann Med 2008;265:30-38.
26. Semb AG, Holme I, Kvien TK, et al. Intensive lipid lowering in patients with rheumatoid arthritis [abstract]. Ann Rheum Dis 2009;68(Suppl 3):410.
27. TRACE-RA. http://www.dgoh.nhs.uk/tracera/. 2008. (accessed 1 Jun 2010).
28. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):E1-40.
29. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
30. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
31. Heldenberg D, Caspi D, Levtov O, et al. Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin Rheumatol 1983;2:387-91.
32. Lorber M, Aviram M, Linn S, et al. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol 1985;24:250-5.
33. Lakatos J, Hárságyi A. Serum total, HDL, LDL cholesterol, and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988;21:93-6.
34. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994;53:551-2.
35. Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. Atherosclerosis 2007;195:e135-41.
36. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746-53.
37. Dursunoglu D, Evrengül H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005;25:241-5.
38. Sattar N, Crompton P, Cherry L, et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2007;56:831-9.
39. Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation. Clin Sci 2005;109:171-6.
40. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001;44:2761-7.
41. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007;49:547-53.
42. Camejo G, Hurt-Camejo E, Wiklund O, et al. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998;139:205-22. (Pubitemid 28361804)
43. Hurt-Camejo E, Camejo G, Rosengren B, et al. Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 1990;31:1387-98.
44. Bashir S, Harris G, Denman MA, et al. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993;52:659-66.
45. Paredes S, Girona J, Hurt-Camejo E, et al. Antioxidant vitamins and lipid peroxidation in patients with rheumatoid arthritis: association with inflammatory markers. J Rheumatol 2002;29:2271-7.
46. Tanimoto N, Kumon Y, Suehiro T, et al. Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003;72:2877-85.
47. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
48. Pruzanski W, Stefanski E, de Beer FC, et al. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. J Lipid Res 1998;39:2150-60.
49. Sierra-Johnson J, Romero-Corral A, Somers VK, et al. ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J 2007;28:2637-43.
50. Sierra-Johnson J, Fisher RM, Romero-Corral A, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009;30:710-17.
51. McQueen MJ, Hawken S, Wang X, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008;372:224-33.
52. Parish S, Peto R, Palmer A, et al. The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009;30:2137-46.
53. Krishnan E, Lingala VB, Singh G. Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 2004;110:1774-9.
54. Choi HK, Hernán MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
55. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18. (Pubitemid 40995372)